JAK1 S703I

CI-VAR-00004107Explore in graph →ENST00000342505.4:c.2108G>TCIViC 822

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hepatocellular Carcinoma1
JAK1 S703I	Ruxolitinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID1900 A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX mod… (full text at CIViC) PMID 26701727 · Yang et al., 2016 · Open in CIViC	civic
Unmapped disease1unmapped disease
JAK1 S703I	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID10051 HEK293FT cells were transfected with JAK1 WT or mutants (N451S, E483D, S703I, A1086S, S729C) following which phosphorylation of JAK1, STAT3 and STAT5 were measured. Both the known activating mutation … (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.